Literature DB >> 8175218

Does captopril treatment before thrombolysis in acute myocardial infarction attenuate reperfusion damage? Short-term and long-term effects.

P Di Pasquale1, S Paterna, S Cannizzaro, V Bucca.   

Abstract

Several experimental studies carried out on animals and on isolated heart preparations show that captopril can reduce post-ischemic reperfusion injury. Our study was aimed at investigating the effects of captopril before thrombolysis in acute myocardial infarction (AMI) and included 259 patients, hospitalized within 4 h of the onset of symptoms. Patients were randomly subdivided into two groups: the first group (131 patients, Group A, pretreatment) received 6.25 mg captopril orally about 15 min before i.v. administration of urokinase (2 million), the second group (128 patients, Group B, late-treatment), received captopril about 3 days after thrombolytic treatment. Captopril doses were later increased in both groups according to blood pressure. All patients were subdivided according to the localization of infarction. Anterior AMI was shown by 166 patients (84 from Group A and 82 from Group B); 93 patients showed inferior AMI (47 from Group A and 46 from Group B). Ventricular hyperkinetic arrhythmias (VHAs) due to reperfusion were evaluated during the first 2 h. VHAs occurred in 11.9% of patients with anterior AMI in Group A vs. 37.8% in Group B (P < 0.001). CK peak normalization time in the group with anterior AMI was achieved after 58 +/- 2 h in Group A vs. 71 +/- 2 h in Group B (P < 0.001). CK peak was 1719 +/- 152 in Group A vs. 2184 +/- 164 U/l in Group B, (P < 0.039). Late arrhythmias, higher than Lown's Class 2 were found to occur in 15.4% of patients with anterior AMI of Group A vs. 31.7% in Group B (P < 0.022), at predischarge Holter test.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175218     DOI: 10.1016/0167-5273(94)90089-2

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Preventive treatment of postinfarction heart rupture.

Authors:  J T Beranek
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

Review 2.  Intramyocardial haemorrhage after acute myocardial infarction.

Authors:  Ryanne P Betgem; Guus A de Waard; Robin Nijveldt; Aernout M Beek; Javier Escaned; Niels van Royen
Journal:  Nat Rev Cardiol       Date:  2014-11-18       Impact factor: 32.419

3.  Effects of administration of captopril, metoprolol, and the captopril-metoprolol combination as adjuvant therapy during thrombolysis in acute myocardial infarction.

Authors:  P Di Pasquale; S Paterna; V Bucca; G Licata
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

4.  Effects of captopril on plasma endothelin-1 during thrombolysis: preliminary findings.

Authors:  P Di Pasquale; S Paterna; G Parrinello; V Bucca; R Caracausi; F Pipitone; G Licata
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

Review 5.  Mechanisms of cell death in acute myocardial infarction: pathophysiological implications for treatment.

Authors:  C de Zwaan; M J A P Daemen; W Th Hermens
Journal:  Neth Heart J       Date:  2001-04       Impact factor: 2.380

Review 6.  Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin.

Authors:  G Heusch; J Rose; T Ehring
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 7.  Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.